Printable version |
The search for a safe and effective HIV vaccine has progressed further and faster in the last few years than at any time since the epidemic began. This progress poses new questions, new opportunities and new challenges as to what and how the HIV vaccine research endeavor should move forward.  In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues. We Want to Hear From You!
Tell us what priority issues/opportunities you believe will facilitate HIV vaccine research and development. Individuals, groups and organizations are invited to submit ideas/topics at any time, submitted ideas will be reviewed on a rolling basis. If selected, we will work with you to develop and implement a plan to convene and address the proposed issue/opportunity and will provide full or partial support for the convening depending on the opportunity. Learn more about the process to submit and evaluate topics here.
|
Upcoming Timely Topics HIV Prevention Trials in Infants Vaccine-Induced Sero-Positivity (VISP) Bench to Clinic Roadmap Strengthening data-sharing policies in funding awards to broaden access to HIV vaccine research Mucosal Sampling |
 |
|
 |
|||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||
